Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in rats

Journal of Pharmacokinetics and Pharmacodynamics
Rutwij A Dave, Marilyn E Morris

Abstract

This study developed a semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated active reabsorption. The model was applied to data for the drug of abuse γ-hydroxybutyric acid (GHB), which exhibits monocarboxylate transporter (MCT1/SMCT1)-mediated renal reabsorption. The kidney model consists of various nephron segments--proximal tubules, Loop-of-Henle, distal tubules, and collecting ducts--where the segmental fluid flow rates, volumes, and sequential reabsorption were incorporated as functions of the glomerular filtration rate. The active renal reabsorption was modeled as vectorial transport across proximal tubule cells. In addition, the model included physiological blood, liver, and remainder compartments. The population pharmacokinetic modeling was performed using ADAPT5 for GHB blood concentration-time data and cumulative amount excreted unchanged into urine data (200-1000 mg/kg IV bolus doses) from rats [Felmlee et al (PMID: 20461486)]. Simulations assessed the effects of inhibition (R = [I]/KI = 0-100) of renal reabsorption on systemic exposure (AUC) and renal clearance of GHB. Visual predictive checks and other model diagnostic plots indicated that the model reasonab...Continue Reading

References

Jun 1, 1979·Clinical Pharmacology and Therapeutics·A ArvidssonG Alván
Jun 1, 1979·Journal of Pharmaceutical Sciences·R E GalinskyG Levy
Apr 1, 1977·The American Journal of Medicine·G Levy
Jul 1, 1976·Journal of Clinical Pharmacology·G Levy, R Koysooko
Dec 1, 1975·Clinical Pharmacology and Therapeutics·S OieG Levy
Dec 19, 1975·European Journal of Clinical Pharmacology·S Oie, G Levy
Dec 1, 1973·The Journal of Clinical Investigation·P B Woodhall, C C Tisher
Aug 31, 1972·The New England Journal of Medicine·G Levy, T Tsuchiya
Jul 5, 1971·JAMA : the Journal of the American Medical Association·G Levy, J R Leonards
Apr 1, 1970·The American Journal of Physiology·W J JuskoG Levy
Apr 1, 1970·Journal of Pharmaceutical Sciences·W J JuskoR Gorodischer
Jun 1, 1970·Journal of Pharmaceutical Sciences·W J Jusko, G Levy
Jan 1, 1969·Journal of Pharmaceutical Sciences·W J Jusko, G Levy
Feb 1, 1966·British Journal of Pharmacology and Chemotherapy·A J CummingsR Renton
Nov 1, 1966·Journal of Pharmaceutical Sciences·G LevyS R Oles
Nov 1, 1966·Journal of Pharmaceutical Sciences·G Levy, W J Jusko
Jan 1, 1967·Journal of Pharmaceutical Sciences·W J Jusko, G Levy
Sep 1, 1967·Journal of Pharmaceutical Sciences·W J Jusko, G Levy
Aug 1, 1984·Journal of Pharmaceutical Sciences·M E Morris, G Levy
Jan 1, 1984·European Journal of Clinical Pharmacology·J Hendel, A Nyfors
Feb 1, 1983·Journal of Pharmaceutical Sciences·D D Tang-LiuS Riegelman
Dec 1, 1981·British Journal of Clinical Pharmacology·G T Tucker
Jan 1, 1981·European Journal of Clinical Pharmacology·T E Sand, S Jacobsen
Apr 1, 1980·Journal of Pharmaceutical Sciences·G Levy
Oct 1, 1980·British Journal of Clinical Pharmacology·G Levy
Jan 1, 1993·European Journal of Clinical Pharmacology·P PalatiniS D Ferrara
Nov 14, 1997·The American Journal of Clinical Nutrition·J BlanchardM Rowland
Mar 4, 1998·Experimental Physiology·G RomanoE Bartoli
Jul 6, 2000·Southern Medical Journal·R H SchwartzM A LeBeau
May 16, 2001·American Journal of Physiology. Renal Physiology·A M Weinstein
Jun 27, 2003·Annals of Emergency Medicine·Karl A SporerRyan Lamb
Nov 1, 1954·The American Journal of Physiology·L G WESSON
Mar 1, 1965·Journal of Pharmaceutical Sciences·G LEVY
Aug 1, 1965·The American Journal of the Medical Sciences·G LEVY
Jan 16, 2004·Trends in Pharmacological Sciences·C Guin Ting WongO Carter Snead
Apr 2, 2004·Biological & Pharmaceutical Bulletin·Kazuhiro WatanabeJuichi Sato
Feb 22, 2005·The Journal of Pharmacology and Experimental Therapeutics·Marilyn E MorrisQi Wang
Sep 2, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Takashi IwanagaIkumi Tamai
Nov 2, 2005·The Journal of Pharmacy and Pharmacology·Hideki FujinoJunji Kojima

❮ Previous
Next ❯

Citations

Apr 2, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Daniel ScotcherAleksandra Galetin
Sep 26, 2015·Journal of Pharmacokinetics and Pharmacodynamics·Ho-Leung Fung, William J Jusko
Nov 11, 2018·The Journal of Pharmacology and Experimental Therapeutics·Takanobu MatsuzakiAmin Rostami-Hodjegan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.